Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

Inclusion Criteria: * Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or diagnosis of recurrent chronic lymphocytic leukemia * Patient has received at least one prior treatment with standard chemotherapy and at least one prior treatment with rituximab (negative HAHA test required if received prior humanized antibody treatment) * Patient has not received anti-cancer therapy within 28 days of treatment unless disease progression has been demonstrated and toxicities from prior therapy have resolved * Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative analyses (paraffin or frozen, recent or archived) * Measurable disease as defined by a tumor mass \> 1.5 cm in one dimension or WBC \> 5,000 (CLL patients) * Age \> 18 years * Patient has KPS \> 50% * Absolute granulocyte count \> 1000 cells/mm3 * Platelet count \> 50,000 cells/mm3 * Creatinine \< 2.0 x ULN * Total bilirubin \< 2.0 x ULN * Patient agrees to use birth control if of reproductive potential * Patient has signed IRB-approved informed consent Exclusion Criteria: * Known central nervous system (CNS) involvement by lymphoma * Known HIV disease * Patient is pregnant or nursing * Patient is receiving other investigational drugs * Known serum human anti-human antibodies (HAHA) * Estimated life expectancy of \< 3 months